ENTX
Entera Bio Ltd.NASDAQHealthcare$1.26-5.56%ClosedMarket Cap: $57.8M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
4.20
P/S
1299.29
EV/EBITDA
-4.19
DCF Value
$0.14
FCF Yield
-37.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
-35.7%
Operating Margin
-27450.0%
Net Margin
-27235.7%
ROE
-70.4%
ROA
-71.5%
ROIC
-218.8%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-3.0M | $-3.0M | $-0.07 | — |
| FY 2025 | $42.0K | -71.4% | $-11.5M | $-11.4M | $-0.25 | — |
| Q3 2025 | $0.00 | -Infinity% | $-3.3M | $-3.2M | $-0.07 | — |
| Q2 2025 | $0.00 | NaN% | $-2.7M | $-2.7M | $-0.06 | — |
| Q1 2025 | $42.0K | 0.0% | $-2.6M | $-2.6M | $-0.06 | — |
| Q4 2024 | $82.0K | 0.0% | $-2.3M | $-2.4M | $-0.06 | — |
| FY 2024 | $181.0K | 5.0% | $-9.6M | $-9.5M | $-0.25 | — |
| Q3 2024 | $42.0K | 0.0% | $-3.0M | $-3.0M | $0.08 | — |
| Q2 2024 | $57.0K | 15.8% | $-2.2M | $-2.1M | $-0.06 | — |
| Q1 2024 | $0.00 | -Infinity% | $-2.1M | $-2.0M | $-0.05 | — |
| Q4 2023 | $0.00 | -Infinity% | $-2.0M | $-2.0M | $-0.07 | — |
| FY 2023 | $0.00 | -Infinity% | $-8.9M | $-8.9M | $-0.31 | — |